✦ LIBER ✦

Presentation, treatment, and outcome of type 1 gastric carcinoid tumors

✍ Scribed by Gregory F. Dakin; Richard R.P. Warner; Alfons Pomp; Barry Salky; William B. Inabnet

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 113 KB
Volume: 93
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.20468

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of gastric argyrophil carcin

Development of gastric argyrophil carcinoid tumors in a case of zollinger-ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment

✍ Professor Michel Mignon; Therese Lehy; Andre Bonnefond; Philippe Ruszniewski; Da 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB 👁 2 views

Distinctive clinical phenotype and treat

Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly

✍ Albert J. Czaja; Herschel A. Carpenter 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Autoimmune hepatitis is classically a disease of young women. Our aims were to determine its occurrence, clinical phenotype, and outcome in elderly patients and contrast findings to young adults. Two-hundred-and-five white North American adults with definite type 1 autoimmune hepatitis were grouped

Present and future perspectives on the u

Present and future perspectives on the use of free or encapsulated pancreatic islet cell transplantation as a treatment of pregnancy complicated by Type 1 diabetes

✍ Stephen K. Hunter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Pregnancies complicated by insulin-dependent diabetes mellitus (IDDM) pose significant health risks to both the mother and her developing fetus. Congenital malformations in the offspring of diabetic mothers have an incidence which is 2-5 times that seen in the background. Euglycemia in the first tri

Combination benefit of treatment with th

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

✍ Alison M. Bendele; Elizabeth S. Chlipala; Jon Scherrer; Janet Frazier; Gina Senn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 695 KB

Objective. To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type II collagen-induced arthri